Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0

作者：

Craig Leonardi

Kristian Reich

Peter Foley

Hideshi Torii

Sascha Gerdes

Lyn Guenther

Melinda Gooderham

Laura K. Ferris

Christopher E. M. Griffiths

Hany ElMaraghy

Heidi Crane

Himanshu Patel

Russel Burge

Gaia Gallo

David Shrom

Ann Leung

Chen-Yen Lin

Kim Papp

机构：

[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing

[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute

[3] Skinflammation® Center,Division of Dermatology

[4] The University of Melbourne,Psoriasis

[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology

[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital

[7] Guenther Dermatology Research Centre,undefined

[8] SkiN Centre for Dermatology and Probity Medical Research,undefined

[9] University of Pittsburgh Medical Center,undefined

[10] University of Manchester,undefined

[11] Eli Lilly and Company,undefined

[12] Lilly Corporate Center,undefined

[13] Syneos Health,undefined

[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined

来源：

Dermatology and Therapy | 2020年 / 10卷

关键词：

Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：431 / 447

页数：16

共 50 条

[31] Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
Armstrong, April
Paul, Carle
Puig, Luis
Boehncke, Wolf Henning
Freeman, Michael
Torii, Hideshi
Papp, Kim
Griffiths, Christopher E. M.
Blauvelt, Andrew
Reich, Kristian
Gooderham, Melinda
Terui, Tadashi
Renda, Lisa
Agada, Noah
Xu, Wen
Gallo, Gaia
Lebwohl, Mark G.
DERMATOLOGY AND THERAPY, 2020, 10 (01) : 133 - 150
[32] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
Gordon, Kenneth B.
Langley, Richard G.
Warren, Richard B.
Okubo, Yukari
Gold, Linda Stein
Merola, Joseph F.
Peterson, Luke
Wixted, Krista
Cross, Nancy
Deherder, Delphine
Thaci, Diamant
JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
[33] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Papp, Kim A.
de Vente, Saskia
Zeng, Jiewei
Flack, Mary
Padilla, Byron
Tyring, Stephen K.
DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
[34] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Kim A. Papp
Saskia de Vente
Jiewei Zeng
Mary Flack
Byron Padilla
Stephen K. Tyring
Dermatology and Therapy, 2021, 11 : 487 - 497
[35] Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
Lebwohl, Mark
Leonardi, Craig
Griffiths, Christopher E. M.
Prinz, Joerg C.
Szapary, Philippe O.
Yeilding, Newman
Guzzo, Cynthia
Li, Shu
Hsu, Ming-Chun
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (05) : 731 - 741
[36] Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Saeki, Hidehisa
Nakagawa, Hidemi
Nakajo, Ko
Ishii, Taeko
Morisaki, Yoji
Aoki, Takehiro
Cameron, Gregory S.
Osuntokun, Olawale O.
JOURNAL OF DERMATOLOGY, 2017, 44 (04) : 355 - 362
[37] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
Zhao, Yan
Zhang, Litao
Wu, Liming
Yang, Bin
Wang, Jinyan
Li, Yumei
Li, Jingyi
Diao, Qingchun
Sun, Qing
Zhu, Xiaohong
Man, Xiaoyong
Wang, Lihua
Li, Linfeng
Feng, Yanyan
Zeng, Huiming
Cai, Tao
Ren, Hong
Lu, Jianyun
Lu, Qianjin
Tao, Xiaohua
Xiao, Rong
Ji, Chao
Li, Fuqiu
Zhang, Jianzhong
ALLERGY, 2024,
[38] Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials
Langley, Richard G.
Sofen, Howard
Dei-Cas, Ignacio
Reich, Kristian
Sigurgeirsson, Bardur
Warren, Richard B.
Paul, Carle
Szepietowski, Jacek C.
Tsai, Tsen-Fang
Hampele, Isabelle
You, Ruquan
Charef, Pascal
Papavassilis, Charis
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (02) : 198 - 207
[39] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
Ohtsuki, Mamitaro
Morita, Akimichi
Abe, Masatoshi
Takahashi, Hidetoshi
Seko, Noriko
Karpov, Alexander
Shima, Tomohiro
Papavassilis, Charis
Nakagawa, Hidemi
JOURNAL OF DERMATOLOGY, 2014, 41 (12) : 1039 - 1046
[40] Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial
Guenther, Lyn
Potts Bleakman, Alison
Weisman, Jamie
Poulin, Yves
Spelman, Lynda
Burge, Russel
Erickson, Janelle
Todd, Kristin
Bertram, Clinton C.
Ryan, Caitriona
ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)

← 1 2 3 4 5 →